Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8<sup>+</sup> Lung-Resident Memory T Cells.

Knight, Frances C; Gilchuk, Pavlo; Kumar, Amrendra; Becker, Kyle W; Sevimli, Sema; Jacobson, Max E; Suryadevara, Naveenchandra; Wang-Bishop, Lihong et al. · ACS Nano · 2019

basic_science · Level V

Where this comes from

Abstract

Tissue-resident memory T cells (T<sub>RM</sub>) patrol nonlymphoid organs and provide superior protection against pathogens that commonly infect mucosal and barrier tissues, such as the lungs, intestine, liver, and skin. Thus, there is a need for vaccine technologies that can induce a robust, protective T<sub>RM</sub> response in these tissues. Nanoparticle (NP) vaccines offer important advantages over conventional vaccines; however, there has been minimal investigation into the design of NP-based vaccines for eliciting T<sub>RM</sub> responses. Here, we describe a pH-responsive polymeric nanoparticle vaccine for generating antigen-specific CD8<sup>+</sup> T<sub>RM</sub> cells in the lungs. With a single intranasal dose, the NP vaccine elicited airway- and lung-resident CD8<sup>+</sup> T<sub>RM</sub> cells and protected against respiratory virus challenge in both sublethal (vaccinia) and lethal (influenza) infection models for up to 9 weeks after immunization. In elucidating the contribution of material properties to the resulting T<sub>RM</sub> response, we found that the pH-responsive activity of the carrier was important, as a structurally analogous non-pH-responsive control carrier elicited significantly fewer lung-resident CD8<sup>+</sup> T cells. We also demonstrated that dual-delivery of protein antigen and nucleic acid adjuvant on the same NP substantially enhanced the magnitude, functionality, and longevity of the antigen-specific CD8<sup>+</sup> T<sub>RM</sub> response in the lungs. Compared to administration of soluble antigen and adjuvant, the NP also mediated retention of vaccine cargo in pulmonary antigen-presenting cells (APCs), enhanced APC activation, and increased production of T<sub>RM</sub>-related cytokines. Overall, these data suggest a promising vaccine platform technology for rapid generation of protective CD8<sup>+</sup> T<sub>RM</sub> cells in the lungs.

Medical subject headings